Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia

BACKGROUND: Tisagenlecleucel is an anti-CD19 chimeric antigen receptor (CAR19) T-cell therapy approved for the treatment of children and young adults with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). METHODS: We evaluated the cellular kinetics of tisagenlecleucel, the effec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Mueller, Karen Thudium, Waldron, Edward, Grupp, Stephan A., Levine, John E., Laetsch, Theodore W., Pulsipher, Michael A., Boyer, Michael W., August, Keith J., Hamilton, Jason, Awasthi, Rakesh, Stein, Andrew M., Sickert, Denise, Chakraborty, Abhijit, Levine, Bruce L., June, Carl H., Tomassian, Lori, Shah, Sweta S., Leung, Mimi, Taran, Tetiana, Wood, Patricia A., Maude, Shannon L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7433345/
https://ncbi.nlm.nih.gov/pubmed/30190371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0758
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados